Advertise
Resources
Member, Beacon International Group, Ltd.
The Centers for Medicare and Medicaid Services on Feb. 22 said it will not reconsider strict coverage limits put in place last year for new Alzheimer's treatments, rejecting a request from the Alzheimer's Association, reports Reuters. The CMS said it would allow coverage for drugs designed to clear amyloid plaques from the brains of Alzheimer's patients only if a medication is approved under the Food and Drug Administration's standard review process, not under its accelerated review program.